Balyasny Asset Management
SOPH icon

Balyasny Asset Management’s SOPHiA GENETICS SOPH Stock Holding History

Balyasny Asset Management’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-48,277
Closed -$123K – 2871
2023
Q3 		$123K Sell
48,277
-54,730
-53% -$174K ﹤0.01% 2101
2023
Q2 		$461K Buy
+103,007
New +$466K ﹤0.01% 1876

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Balyasny Asset Management's SOPH Position: Q4 2023 in Review

Balyasny Asset Management sold out of SOPHiA GENETICS (SOPH) in Q4 2023, closing a stake of 48,277 shares — an estimated $123K sold.

Balyasny Asset Management first reported a position in SOPH in Q2 2023 and held it in 2 quarters. The position peaked at $461K in Q2 2023. 36 funds tracked by Wall St. Rank hold SOPH as of Q4 2023.

  • Balyasny Asset Management reported no remaining SOPHiA GENETICS position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 48,277 SOPHiA GENETICS shares in Q4 2023, an estimated $123K.
  • Balyasny Asset Management first reported a position in SOPHiA GENETICS in Q2 2023 and held it in 2 quarters.
  • Balyasny Asset Management's SOPHiA GENETICS position peaked at $461K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.